Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer. read more
Sergio L. Santillana M.D., MSc ā Chief Medical Officer at Merrimack Pharmaceuticals
Executive Bio
Dr. Sergio L. Santillana, M.D., MSc has been Chief Medical Officer at Merrimack Pharmaceuticals, Inc. since June 12, 2017. Dr. Santillana served as the Acting Chief Medical Officer of Ariad Pharmaceuticals Inc since May 6, 2016 until 2017. Dr. Santillana served as Vice President of Clinical R&D at Ariad Pharmaceuticals Inc until May 6, 2016. Prior to joining ARIAD, Dr. Santillana served in various oncology clinical development leadership roles at Takeda, GlaxoSmithKline and Eli Lilly. Before entering the biopharma industry. Dr. Santillana was a practicing board-certified medical oncologist for 15 years, including tenure at the National Cancer Institute of Peru (INEN). Dr. Santillana holds an M.S. in Experimental Therapeutics from Kellogg College at the University of Oxford and an M.D. and B.S. from the Universidad Nacional Federico Villarreal School of Medicine.
Executive Team Culture Ratings from Merrimack Pharmaceuticals Employees
TOP
50%
Merrimack Pharmaceuticals' Executive Team scores in the Top 50%
of similar sized companies on Comparably
of similar sized companies on Comparably
Not Enough Ratings To Show Who Ranks Executive Team the Highest
Anonymously rate my experience at Merrimack PharmaceuticalsNot Enough Ratings To Show Who Ranks Executive Team the Lowest
Anonymously rate my experience at Merrimack PharmaceuticalsMerrimack Pharmaceuticals' Executive Team at a Glance
Based on 6 ratings, Merrimack Pharmaceuticals' employees are less satisfied with their Executive Team and give them a āC+ā or 69/100.
Merrimack Pharmaceuticals' Executive Team ranks in the Top 50% of other companies in Boston and Top 50% of other companies on Comparably that also have 201-500 Employees.
×